Secretome improves anti-Müllerian hormone level and ovarian function in a premature ovarian insufficiency mice model
Stella Kawilarang1, I Gede Eka Wiratnaya2, I Wayan Putu Sutirta Yasa3
1Udayana University Faculty of Medicine, Department of Biomedical Science, Bali, Indonesia.
Objective:
To evaluate the efficacy of secretome in improving the anti-Müllerian hormone (AMH) level and ovarian weight and restoring ovarian function in the premature ovarian insufficiency (POI) model mice.
Materials And Methods:
A randomized, post-test-only control-group design was conducted on 18 mice, which were divided into three groups: A control group and two case groups injected with a secretome. Blood samples were analyzed for the AMH level with an enzyme-linked immunosorbent assay kit; ovarian weight was measured; and hematoxylin-eosin staining was used to measure and categorize follicles at each stage.
Results:
The cyclophosphamide (CTX) group showed significant differences in ovarian weight, AMH, and the numbers of primary, secondary, antral, and atretic follicles compared with the control group, indicating induction of premature ovarian failure. Follicular development was improved in the CTX-secretome group compared to the CTX group, with significantly increased ovarian weight and AMH, increased numbers of primary, secondary, and antral follicles, and decreased numbers of atretic follicles. However, the results showed a significant difference between the CTX-secretome and the control group.
Conclusion:
Our findings show that secretome therapy improved POI management, but the results have not yet restored normal ovarian function. It still does not achieve the same functional state as normal ovarian function. Further research, particularly involving different doses of secretome, is necessary to validate these findings.
